Natco Pharma Ltd.

BSE: NATCOPHARM524816ISIN INE987B01026

Healthcare
Pharmaceuticals
BSE 500

Share price

₹789.60+7.90 (+1.01%)

as of 4 Nov 2026

Prices adjusted for splits and bonuses; cash dividends excluded. Volume shows actual shares traded. Earlier history is omitted pending corporate-action verification.

52W high: —
52W low: —
Off 52W high: —
1M return: -3.96%
3M return: —
6M return: —
1Y return: —
20D avg volume: 34,524
50 DMA: —
200 DMA: —

Key ratios Consolidated

Market cap: ₹15,489 Cr
Current price: ₹789.60
52W high / low: — / —
Face value: ₹2.00
P/E: 13.53
P/B: —
EPS (TTM): ₹58.35
Book value / share: —
ROE: —
ROCE: 16.30%
Operating margin: —
Net margin: —
Debt / equity: 0.08
Net debt: ₹507.50 Cr
Interest cover: 41.62
Dividend yield: 0.57%
Dividend / share (TTM): ₹4.50
Payout: 7.71%
Cash conversion cycle: 123.6 days

Financials

Metric	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24	Q2 FY24
Income statement
	735.20	739.10	647.30	1,363	1,329	1,221	474.80	1,371	1,363	1,068	758.60	1,031
	59.20	77.80	58.10	100.00	61.70	66.30	176.30	63.80	48.10	42.00	37.00	29.40
	794.40	816.90	705.40	1,463	1,391	1,287	651.10	1,435	1,411	1,110	795.60	1,061
	608.80	672.80	544.30	849.30	818.70	781.40	487.40	616.70	607.10	632.70	539.30	621.20
	157.80	102.80	135.20	174.90	180.60	169.00	72.70	143.20	151.30	127.60	92.20	166.50
	27.80	37.50	55.80	72.60	37.30	40.80	39.10	53.70	32.50	31.10	36.70	41.00
	179.30	158.50	159.40	200.30	169.00	159.40	141.60	151.50	142.00	142.50	121.90	122.40
	13.00	10.90	9.50	13.10	3.20	10.20	4.40	4.10	5.20	6.20	4.60	4.20
	47.10	50.40	46.20	52.40	57.60	98.30	47.00	45.80	44.10	55.50	44.20	43.60
	221.90	298.30	196.10	413.80	355.90	264.30	211.60	237.70	235.60	285.90	206.40	235.20
	185.60	144.10	161.10	613.70	571.90	505.90	163.70	818.20	803.60	477.60	256.30	439.60
	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	185.60	144.10	161.10	613.70	571.90	505.90	163.70	818.20	803.60	477.60	256.30	439.60
	63.40	89.20	20.70	95.80	91.60	99.90	31.30	141.70	135.10	91.30	43.60	70.60
	206.50	269.00	151.30	517.90	480.30	406.00	132.40	676.50	668.50	386.30	212.70	369.00
	11.53	14.96	8.46	28.94	26.84	22.70	7.43	37.81	37.32	21.56	11.88	20.60
Key metrics
	245.70	205.40	216.80	679.20	632.70	614.40	215.10	868.10	852.90	539.30	305.10	487.40
	33.40%	27.80%	33.50%	49.80%	47.60%	50.30%	45.30%	63.30%	62.60%	50.50%	40.20%	47.30%
	28.10%	36.40%	23.40%	38.00%	36.10%	33.30%	27.90%	49.30%	49.10%	36.20%	28.00%	35.80%
	—	1.70%	—	7.20%	—	6.70%	—	—	—	—	—	—
	-44.70%	-39.50%	36.30%	-0.60%	-2.50%	14.30%	-37.40%	32.90%	—	—	—	—
	-57.00%	-33.70%	14.30%	-23.40%	-28.20%	5.10%	-37.80%	83.30%	—	—	—	—

Metric	TTM	FY26	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17
Income statement
	3,485	4,078	4,430	3,999	2,707	1,945	2,052	1,915	2,094	2,202	2,065
	295.10	297.60	354.50	128.10	104.60	99.00	103.60	107.40	130.20	40.40	13.90
	3,780	4,376	4,784	4,127	2,812	2,044	2,156	2,022	2,225	2,242	2,079
	2,675	2,885	2,493	2,453	1,950	1,842	1,576	1,454	1,400	1,355	1,454
	570.70	593.50	536.20	522.50	475.30	519.20	372.90	329.00	333.10	390.50	520.80
	193.70	203.20	166.10	151.40	175.70	58.50	186.60	127.80	55.00	45.90	97.10
	697.50	687.20	594.50	525.00	486.70	444.80	414.90	375.00	355.90	325.60	243.20
	46.50	36.70	23.90	19.20	14.50	17.70	13.30	21.50	19.30	15.40	18.50
	196.10	206.60	235.20	186.80	163.80	142.60	116.90	99.80	81.00	—	54.40
	1,130	1,264	949.20	1,006	—	675.60	—	—	589.60	519.70	539.30
	1,104	1,491	2,291	1,674	861.90	202.20	579.60	568.70	824.70	887.20	624.40
	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	1,104	1,491	2,291	1,674	861.90	202.20	579.60	568.70	824.70	887.20	624.40
	269.10	118.90	408.00	285.20	146.60	32.20	137.20	110.60	182.30	192.00	139.50
	1,145	1,418	1,883	1,388	715.30	170.00	442.40	458.10	642.40	695.20	484.90
	63.89	79.20	105.26	77.34	39.18	9.32	24.20	25.33	34.98	—	—
Key metrics
	1,347	1,734	2,550	1,880	1,040	362.50	709.80	690.00	925.00	902.60	697.30
	38.66%	42.50%	57.60%	47.00%	38.40%	18.60%	34.60%	36.00%	44.20%	41.00%	33.80%
	32.85%	34.80%	42.50%	34.70%	26.40%	8.70%	21.60%	23.90%	30.70%	31.60%	23.50%
	—	16.30%	30.10%	—	—	—	—	—	—	—	—
	-20.73%	-7.90%	10.80%	47.70%	39.20%	-5.20%	7.20%	-8.60%	-4.90%	6.60%	—
	-32.47%	-24.70%	35.70%	94.10%	320.80%	-61.60%	-3.40%	-28.70%	-7.60%	43.40%	—
	—	1,380	1,296	—	—	—	—	—	—	—	—
	—	1.25	0.90	—	—	—	—	—	—	—	—
	—	0.08	0.04	—	—	—	—	—	—	—	—
	—	507.50	153.10	—	—	—	—	—	—	—	—
	—	123.6	143.1	—	—	—	—	—	—	—	—
Balance sheet
	—	11,074	8,631	—	—	—	—	—	—	—	—
	—	5,052	5,270	—	—	—	—	—	—	—	—
	—	198.90	120.00	—	—	—	—	—	—	—	—
	—	881.20	1,247	—	—	—	—	—	—	—	—
	—	908.50	765.80	—	—	—	—	—	—	—	—
	—	381.90	330.90	—	—	—	—	—	—	—	—
	—	2,545	2,432	—	—	—	—	—	—	—	—
	—	409.30	274.90	—	—	—	—	—	—	—	—
	—	1,681	943.50	—	—	—	—	—	—	—	—
	—	706.40	273.10	—	—	—	—	—	—	—	—
	—	606.40	273.10	—	—	—	—	—	—	—	—
	—	100.00	0.00	—	—	—	—	—	—	—	—
	—	9,221	7,612	—	—	—	—	—	—	—	—
Cash flow
	—	1,768	1,697	—	—	—	—	—	—	—	—
	—	-2,143	-1,414	—	—	—	—	—	—	—	—
	—	297.50	-210.70	—	—	—	—	—	—	—	—
	—	388.30	401.10	—	—	—	—	—	—	—	—

Metric	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24	Q2 FY24
Income statement
	596.60	608.80	528.80	1,264	1,193	1,157	407.60	1,293	1,237	964.80	625.30	930.50
	48.30	72.90	55.30	93.30	59.60	62.10	168.00	51.40	39.80	35.90	29.50	24.70
	644.90	681.70	584.10	1,358	1,252	1,220	575.60	1,344	1,277	1,001	654.80	955.20
	542.90	571.70	458.90	771.60	709.40	698.70	425.30	547.10	518.70	568.20	431.20	531.20
	157.80	102.80	135.20	174.90	180.60	169.00	72.70	143.20	151.30	127.60	92.20	166.60
	0.40	13.30	7.60	20.60	7.90	9.70	14.80	13.30	7.70	8.00	11.10	6.80
	151.40	133.10	136.50	178.60	143.50	138.70	123.60	132.80	120.20	125.00	103.90	106.80
	9.60	9.70	8.30	11.70	2.60	8.80	3.40	3.00	4.40	4.50	3.80	3.00
	42.70	45.60	42.10	48.10	53.80	93.70	43.70	42.20	40.40	51.60	40.40	40.00
	182.50	259.50	160.30	378.70	325.80	235.90	184.30	213.30	208.10	281.20	172.40	200.50
	102.00	110.00	125.20	586.00	542.90	520.80	150.30	796.90	758.00	432.50	223.60	424.00
	0.00	0.00	0.00	0.00	0.00	0.00	—	—	—	—	—	—
	102.00	110.00	125.20	586.00	542.90	520.80	150.30	796.90	758.00	432.50	223.60	424.00
	27.40	-99.60	18.30	85.10	78.80	92.70	25.40	135.80	121.70	83.40	31.60	63.80
	74.60	209.60	106.90	500.90	464.10	428.10	124.90	661.10	636.30	349.10	192.00	360.20
	4.17	11.70	5.97	27.97	25.91	23.90	6.97	36.91	35.53	19.49	10.72	20.11
Key metrics
	154.30	165.30	175.60	645.80	599.30	623.30	197.40	842.10	802.80	488.60	267.80	467.00
	25.90%	27.20%	33.20%	51.10%	50.20%	53.90%	48.40%	65.10%	64.90%	50.60%	42.80%	50.20%
	12.50%	34.40%	20.20%	39.60%	38.90%	37.00%	30.60%	51.10%	51.40%	36.20%	30.70%	38.70%
	—	1.40%	—	7.20%	—	7.20%	—	—	—	—	—	—
	-50.00%	-47.40%	29.70%	-2.20%	-3.60%	20.00%	-34.80%	38.90%	—	—	—	—
	-83.90%	-51.00%	-14.40%	-24.20%	-27.10%	22.60%	-34.90%	83.50%	—	—	—	—

Metric	TTM	FY26	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17
Income statement
	2,998	3,595	4,094	3,569	2,351	1,768	1,654	1,790	1,986	2,108	2,003
	269.80	281.10	321.30	104.70	85.50	94.60	101.10	123.80	129.80	39.40	13.20
	3,268	3,876	4,416	3,674	2,436	1,862	1,755	1,914	2,116	2,148	2,016
	2,345	2,512	2,190	2,118	1,666	1,706	1,362	1,331	1,269	1,260	1,382
	570.70	593.50	536.20	522.50	475.30	519.20	372.90	329.00	333.10	390.50	520.80
	41.90	49.40	45.50	34.80	19.80	20.90	174.00	123.90	31.50	22.70	68.70
	599.60	591.70	515.30	454.90	425.70	410.10	380.00	356.10	340.20	312.20	232.10
	39.30	32.30	19.60	14.50	8.60	13.30	11.30	20.60	18.80	14.70	17.50
	178.50	189.60	220.00	171.90	150.90	138.40	115.20	98.10	80.10	65.50	53.60
	981.00	1,124	841.60	902.50	—	—	—	—	490.50	462.20	505.90
	923.20	1,364	2,226	1,555	770.70	155.90	392.20	583.10	847.40	887.60	634.10
	0.00	0.00	0.00	—	—	—	—	—	—	—	—
	923.20	1,364	2,226	1,555	770.70	155.90	392.20	583.10	847.40	887.60	634.10
	31.20	82.60	375.60	248.70	133.60	16.80	82.70	108.60	180.30	189.40	139.30
	892.00	1,282	1,850	1,307	637.10	139.10	309.50	474.50	667.10	698.20	494.80
	49.81	71.55	103.31	72.79	34.90	7.63	16.99	26.08	36.22	—	—
Key metrics
	1,141	1,586	2,466	1,742	930.20	307.60	518.70	701.80	946.30	967.80	705.20
	38.05%	44.10%	60.20%	48.80%	39.60%	17.40%	31.40%	39.20%	47.60%	45.90%	35.20%
	29.75%	35.70%	45.20%	36.60%	27.10%	7.90%	18.70%	26.50%	33.60%	33.10%	24.70%
	—	16.00%	30.30%	—	—	—	—	—	—	—	—
	-25.97%	-12.20%	14.70%	51.80%	33.00%	6.90%	-7.60%	-9.90%	-5.80%	5.30%	—
	-46.85%	-30.70%	41.60%	105.10%	358.00%	-55.10%	-34.80%	-28.90%	-4.50%	41.10%	—
	—	1,393	1,258	—	—	—	—	—	—	—	—
	—	1.39	0.90	—	—	—	—	—	—	—	—
	—	0.08	0.04	—	—	—	—	—	—	—	—
	—	694.90	261.90	—	—	—	—	—	—	—	—
	—	113.5	142.1	—	—	—	—	—	—	—	—
Balance sheet
	—	10,287	8,270	—	—	—	—	—	—	—	—
	—	4,320	4,688	—	—	—	—	—	—	—	—
	—	11.50	11.20	—	—	—	—	—	—	—	—
	—	759.60	1,178	—	—	—	—	—	—	—	—
	—	723.60	642.10	—	—	—	—	—	—	—	—
	—	332.00	298.40	—	—	—	—	—	—	—	—
	—	2,520	2,410	—	—	—	—	—	—	—	—
	—	365.30	225.10	—	—	—	—	—	—	—	—
	—	1,566	864.60	—	—	—	—	—	—	—	—
	—	706.40	273.10	—	—	—	—	—	—	—	—
	—	606.40	273.10	—	—	—	—	—	—	—	—
	—	100.00	0.00	—	—	—	—	—	—	—	—
	—	8,553	7,334	—	—	—	—	—	—	—	—
Cash flow
	—	1,776	1,662	—	—	—	—	—	—	—	—
	—	-2,078	-1,444	—	—	—	—	—	—	—	—
	—	302.10	-212.40	—	—	—	—	—	—	—	—
	—	383.30	403.70	—	—	—	—	—	—	—	—

Compounded growth

Standalone

Sales CAGR 3Y: +15.20%
Sales CAGR 5Y: +16.80%
Profit CAGR 3Y: +26.23%
Profit CAGR 5Y: +32.87%
Sales YoY (TTM): -25.97%
Profit YoY (TTM): -46.85%

Consolidated

Sales CAGR 3Y: +14.64%
Sales CAGR 5Y: +14.72%
Profit CAGR 3Y: +25.64%
Profit CAGR 5Y: +26.24%
Sales YoY (TTM): -20.73%
Profit YoY (TTM): -32.47%

Compounded from reported annual figures. We publish no share-price CAGR: our prices are as-traded, so one would be wrong across every split and bonus issue.

Shareholding as of 30 Oct 2026

Promoter holding: 46.24%

Quarter	30 Oct 2026	September 2026
Promoter %	46.24%	46.24%

Holder	Type	Holding	Previous	Change
V C NANNAPANENI	Promoter	14.60%	14.60%	0.00%
TIME CAP PHARMA LABS PRIVATE LIMITED	Promoter Group	9.23%	9.23%	0.00%
NATSOFT INFORMATION SYSTEMS PVT LTD	Promoter Group	8.17%	8.17%	0.00%
VENKATA SATYA SWATHI KANTAMANI	Promoter Group	8.15%	8.15%	0.00%
TATA MUTUAL FUND	Public	2.58%	2.58%	0.00%
BELGRAVE INVESTMENT FUND	Public	2.42%	2.42%	0.00%
Vistra ITCL India Limited A/c Neelima Nannapaneni Trust	Promoter	2.12%	2.12%	0.00%
LIFE INSURANCE CORPORATION OF INDIA	Public	2.04%	2.04%	0.00%
DURGA DEVI NANNAPANENI	Promoter	1.78%	1.78%	0.00%
ICICI Prudential	Public	1.61%	1.61%	0.00%
NIPPON LIFE INDIA TRUSTEE LTD	Public	1.26%	1.26%	0.00%
ELM PARK FUND LIMITED	Public	1.05%	1.05%	0.00%
AKASH BHANSHALI	Public	1.01%	1.01%	0.00%
RAJEEV NANNAPANENI	Promoter	0.58%	0.58%	0.00%
Vistra ITCL India Limited A/c Durgadevi Family Trust	Promoter	0.31%	0.31%	0.00%

Public shareholders are disclosed individually only above 1%.

Peer comparison

Company	Mkt cap (₹ Cr)	Price (₹)	P/E	ROCE	Sales YoY	Profit YoY	1Y return
Sun Pharmaceutical Industries Ltd.	4,26,112	1,776.00	38.78	17.90%	+12.13% TTM	+4.79% TTM	+4.92%
Divi's Laboratories Ltd.	2,66,424	10,036.00	91.09	19.00%	+16.35% TTM	+26.84% TTM	+47.61%
Torrent Pharmaceuticals Ltd.	1,79,908	4,730.00	85.71	9.10%	+42.06% TTM	-1.92% TTM	+32.24%
Laurus Labs Limited	1,24,601	2,306.10	93.53	19.70%	+23.03% TTM	+95.38% TTM	+134.59%
Zydus Lifesciences Limited	1,18,703	1,190.00	25.85	19.20%	+21.11% TTM	-2.51% TTM	+22.32%
Dr. Reddy's Laboratories Ltd.	1,14,513	1,372.00	41.50	13.90%	-3.53% TTM	-51.90% TTM	+14.26%
Cipla Ltd.	1,13,110	1,400.10	39.63	14.90%	-0.74% TTM	-47.48% TTM	-6.88%
Mankind Pharma Limited	1,04,631	2,533.15	46.22	13.70%	+13.27% TTM	+27.60% TTM	+6.91%
Aurobindo Pharma Ltd.	97,878	1,701.10	26.38	13.60%	+9.09% TTM	+9.48% TTM	+47.79%
Lupin Ltd	92,145	2,015.00	17.65	28.40%	+24.22% TTM	+20.10% TTM	+0.84%
Glenmark Pharmaceuticals ltd	70,608	2,501.85	39.27	16.20%	+32.94% TTM	+138.48% TTM	+35.48%
Alkem Laboratories Limited	62,054	5,190.00	28.15	18.80%	+13.36% TTM	-5.52% TTM	-8.38%
Abbott India Ltd. S	57,685	27,146.85	35.73	41.90%	+6.29% TTM	+11.18% TTM	-7.56%
Biocon Ltd.	56,061	344.00	134.63	2.90%	+5.70% TTM	-55.37% TTM	-9.53%
Gland Pharma Limited	52,105	3,157.70	46.16	13.70%	+17.57% TTM	+46.55% TTM	+65.09%
Ipca Laboratories Ltd.	50,051	1,973.15	36.40	16.40%	+10.59% TTM	+67.91% TTM	+52.33%
GlaxoSmithkline Pharmaceuticals Ltd.	42,904	2,532.60	37.42	55.40%	+12.12% TTM	+20.03% TTM	-4.84%
Ajanta Pharma Ltd.	41,406	3,313.55	32.79	29.40%	+25.01% TTM	+29.70% TTM	+26.89%
Emcure Pharmaceuticals Limited	41,254	2,174.55	37.75	25.10%	+21.12% TTM	+33.34% TTM	+64.07%
J.B. Chemicals & Pharmaceuticals Lt	38,731	2,412.25	47.77	21.90%	+5.87% TTM	+7.56% TTM	+45.79%
Sai Life Sciences Limited	32,855	1,546.30	90.80	18.10%	—	—	+67.49%
PIRAMAL PHARMA LIMITED	31,659	237.80	-151.21	0.80%	+9.43% TTM	-781.93% TTM	+18.60%
ACUTAAS CHEMICALS LIMITED	30,928	3,777.65	70.51	27.70%	+45.18% TTM	+95.78% TTM	+106.30%
Wockhardt Ltd	30,869	1,899.80	76.22	6.40%	+25.70% TTM	+894.12% TTM	+39.18%
RUBICON RESEARCH LIMITED	28,416	1,716.55	98.59	24.30%	—	—	+164.06%
Natco Pharma Ltd.	15,489	789.60	13.53	16.30%	-20.73% TTM	-32.47% TTM	—

Filings & corporate actions

Recent announcements

The Exchange has received revised Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on November 04, 2026 for V C Nannapaneni4 Nov 2026 · Insider Trading / SAST / Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Venkaiah Chowdary Nannapaneni30 Oct 2026 · Insider Trading / SAST / Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
Natco Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/11/2026 ,inter alia, to consider and approve the Un-audited Financial Results ....29 Oct 2026 · Board Meeting / Board Meeting
News Paper Publication for Basis of Allotment of Right Issue29 Oct 2026 · Company Update / Newspaper Publication
Outcome of the Fund-raising Committee meeting approving the allotment of 17058082 Equity shares23 Oct 2026 · Company Update / Allotment of Equity Shares
Update on Trading Window Closure period22 Oct 2026 · Insider Trading / SAST / Closure of Trading Window
Intimation of closure of the Issue period of the Rights Issue of NATCO Pharma Limited (the "Company")22 Oct 2026 · Company Update / General
Natco Pharma announces launch of Carboplatin Injection (generic of Paraplatin) in the U.S. market19 Oct 2026 · Company Update / Press Release / Media Release
Compliance Certificate under Reg.74(5) of SEBI(DP) Regulations, 201816 Oct 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on October 12, 2026 for V C Nannapaneni13 Oct 2026 · Insider Trading / SAST / Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
News Paper Publications7 Oct 2026 · Company Update / Newspaper Publication
Evoting Results along with Scrutinizer Report for the 43rd Annual General Meeting held on 30/09/202630 Sep 2026 · AGM/EGM / AGM
Closure of Trading Window30 Sep 2026 · Insider Trading / SAST / Closure of Trading Window
Proceedings of the 43rd Annual General Meting30 Sep 2026 · AGM/EGM / AGM
Outcome of Fund Raising Committee Meeting approving the Letter of Offer for Rights Issue28 Sep 2026 · Others / Outcome without intimation
Press Release and disclosure under Regulation 30 of SEBI (LODR) Regulations, 201528 Sep 2026 · Company Update / Press Release / Media Release
Newspaper Publication of Record date for Rights Issue26 Sep 2026 · Company Update / Newspaper Publication
Intimation of Record Date for Rights Issue25 Sep 2026 · Corp. Action / Record Date
Out come of Board Meeting25 Sep 2026 · Company Update / Issue of Securities
Natco Pharma Limited has informed the Exchange that Board of Directors at its meeting held on September 25, 2026, has decided to issue equity shares on rights basis in the ratio of 2 : ....25 Sep 2026 · Board Meeting / Outcome of Board Meeting
Natco Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/09/2026 ,inter alia, to consider and approve to consider, discuss and decide ....22 Sep 2026 · Board Meeting / Board Meeting
Receipt of In-principal approval for Rights Issue of Equity Shares21 Sep 2026 · Company Update / General
Draft letter of Offer9 Sep 2026 · Company Update / Issue of Securities
Outcome of Board Meeting9 Sep 2026 · Board Meeting / Outcome of Board Meeting
News Paper Publication5 Sep 2026 · Company Update / Newspaper Publication
Notice of 43rd Annual General Meeting of the Company scheduled to be held on Wednesday, the September 30, 2026 at 11:00 AM (IST)4 Sep 2026 · AGM/EGM / AGM
Business Responsibility and Sustainability Report4 Sep 2026 · Others / Business Responsibility and Sustainability Reporting (BRSR)
Annual Report for the FY 2025-264 Sep 2026 · Others / Reg. 34 (1) Annual Report
Natco Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/09/2026 ,inter alia, to consider and approve Fund Raising4 Sep 2026 · Board Meeting / Board Meeting
Investor Meet2 Sep 2026 · Company Update / Analyst / Investor Meet
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Durga Devi Nannapaneni26 Aug 2026 · Insider Trading / SAST / Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
Press Release & Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015 regarding the investment in eGenesis, Inc.25 Aug 2026 · Company Update / Press Release / Media Release
Intimation of Investor Meet24 Aug 2026 · Company Update / Analyst / Investor Meet
Conclusion of US FDS Inspection at our Visakhapatnam, Andhra Pradesh, Finished Dosage (FDF) Unit21 Aug 2026 · Company Update / Press Release / Media Release
Investor Meet19 Aug 2026 · Company Update / Analyst / Investor Meet
Investor Presentation19 Aug 2026 · Company Update / Investor Presentation
Q1FY2026-27 Transcript for the Earnings call held on 14th August, 202618 Aug 2026 · Company Update / Earnings Call Transcript
Intimation of Investors meeting organised by Nuvama Wealth Management Limited and ICICI Securities Limited16 Aug 2026 · Company Update / Analyst / Investor Meet
Newspaper Publication for the Un-Audited Financial Results for the quarter ended June 30, 2026 and declaration of Interim Dividend for the FY ending 2026-27.16 Aug 2026 · Company Update / Newspaper Publication
Weblink of Audio Transcript for the earnings call held on 14th August, 2026 for Q1FY2026-2714 Aug 2026 · Company Update / Analyst / Investor Meet

Corporate actions

Purpose	Ex date	Record date	Payment date
Right Issue of Equity Shares	1 Oct 2026	1 Oct 2026	—
Interim Dividend - Rs. - 1.5000	20 Aug 2026	20 Aug 2026	—
Interim Dividend - Rs. - 1.5000	18 Feb 2026	18 Feb 2026	—
Interim Dividend - Rs. - 1.5000	20 Nov 2025	20 Nov 2025	—
Interim Dividend - Rs. - 2.0000	19 Aug 2025	19 Aug 2025	—
Interim Dividend - Rs. - 1.5000	18 Feb 2025	18 Feb 2025	—
Interim Dividend - Rs. - 1.5000	27 Nov 2024	27 Nov 2024	—
Interim Dividend - Rs. - 3.0000	23 Aug 2024	23 Aug 2024	—

Board meetings

13 Nov 2026 Board Meeting - Financial Results
14 Aug 2026 Board Meeting - Financial Results